Danaher (NYSE:DHR) Releases FY19 Earnings Guidance

Danaher (NYSE:DHR) issued an update on its FY19 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $4.75-4.80 for the period, compared to the Thomson Reuters consensus estimate of $4.85. Danaher also updated its FY 2019 guidance to $4.75-4.80 EPS.

Shares of DHR traded down $1.04 during mid-day trading on Friday, reaching $141.96. The stock had a trading volume of 23,047 shares, compared to its average volume of 2,196,764. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.74 and a current ratio of 2.18. Danaher has a 52-week low of $94.59 and a 52-week high of $145.50. The company has a fifty day moving average of $140.06. The stock has a market capitalization of $99.98 billion, a price-to-earnings ratio of 31.47, a price-to-earnings-growth ratio of 2.53 and a beta of 0.96.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Thursday, July 18th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.15 by $0.04. Danaher had a net margin of 12.04% and a return on equity of 11.61%. The firm had revenue of $5.16 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the firm posted $1.15 earnings per share. Danaher’s quarterly revenue was up 3.5% on a year-over-year basis. As a group, research analysts forecast that Danaher will post 4.77 EPS for the current fiscal year.



The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.17 dividend. The ex-dividend date is Thursday, June 27th. This represents a $0.68 dividend on an annualized basis and a yield of 0.48%. Danaher’s payout ratio is currently 15.04%.

DHR has been the topic of a number of recent analyst reports. Robert W. Baird reaffirmed an outperform rating and issued a $148.00 target price (up previously from $131.00) on shares of Danaher in a research report on Friday. Piper Jaffray Companies raised shares of Post from a neutral rating to an overweight rating and upped their target price for the company from $106.00 to $130.00 in a research report on Thursday. Wolfe Research initiated coverage on shares of Waters in a research report on Thursday, May 30th. They issued an underperform rating on the stock. Janney Montgomery Scott upped their target price on shares of Danaher from $136.00 to $174.00 and gave the company a buy rating in a research report on Wednesday, April 17th. Finally, Zacks Investment Research cut shares of GALP ENERGIA SG/ADR from a hold rating to a sell rating in a research report on Monday, May 6th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $137.08.

In other news, insider Thomas Patrick Joyce, Jr. sold 14,454 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $132.79, for a total transaction of $1,919,346.66. Following the sale, the insider now owns 200,479 shares of the company’s stock, valued at $26,621,606.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Donald J. Ehrlich sold 5,000 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $132.95, for a total transaction of $664,750.00. Following the sale, the director now directly owns 100,603 shares in the company, valued at approximately $13,375,168.85. The disclosure for this sale can be found here. Insiders sold 453,448 shares of company stock worth $59,724,640 in the last ninety days. 11.40% of the stock is currently owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Further Reading: Technical Analysis of Stocks and What It Means

Earnings History and Estimates for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.